NewcelX Ltd. NCEL 深 沪
已收盘 07-02 16:00:00 美东时间
3.85
0.000
0.00%
华盛通- 最 高4.10
- 今 开4.10
- 成交量 3.75万股
- 最 低 3.68
- 昨 收 3.85
- 总市值 2072.79万
- 52周最高 28.032
- 市盈率 静 --
- 换手率 0.70%
- 52周最低 1.8299
- 委 比 59.00%
- 总股本 538.39万
- 历史最高 2940.00
- 量 比 0.85
- 振 幅 10.91%
- 历史最低 1.8299
- 每 手 1
- 风险率 8.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND Submission
NewcelX submitted an FDA Pre-IND package for NCEL-101 to advance its type 1 diabetes treatment into human trials.
05-27 19:31
NewcelX FY EPS $(2.16) Up From $(2.43) YoY
NewcelX (NASDAQ:NCEL) reported quarterly losses of $(2.16) per share. This is a 11.11 percent increase over losses of $(2.43) per share from the same period last year.
04-30 20:56
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.
04-30 20:01
EXCLUSIVE: NewcelX Expects Expanded Strategic Development Collaborations For Diabetes Drug In 2026
Outlook for 2026The Company expects 2026 to be a year of accelerated execution, including: Advancing NCEL-101 toward key IND-enabling milestones Expanding strategic development collaborations Pursuing additional
04-30 20:00
NewcelX Advances Diabetes Program With New Drug Partnership With Eledon Pharma To Prevent Transplant Rejection
NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that
04-20 19:39
9 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Quince Therapeutics (NASDAQ:QNCX) stock moved upwards by 98.6% to $0.3...
04-08 20:05
NewcelX Enters Securities Purchase Agreements For Private Placement At $2.75 Per Share, 30% Premium To Last Close
Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes programZURICH, Switzerland, April 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage biopharmaceutical
04-01 19:32
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing
Zurich-based biopharmaceutical company NewcelX Ltd. announced a private placement of 490,907 common shares at $2.75 per share, a 30% premium over its March 31 closing price, raising funds to advance its lead Type 1 Diabetes program NCEL-101 in collaboration with Eledon Pharmaceuticals. The offering also includes warrants for 687,270 additional shares at $3.025 per share and is expected to close by April 15. Proceeds will support NCEL-101 developm...
04-01 11:21
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy
Publication strengthens scientific positioning as Company progresses strategic discussions related to CVR-linked asset ZURICH, Feb. 12, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX" or the "C...
02-12 20:00
NewcelX CEO Issues Letter to Shareholders
ZURICH, Nov. 4, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies for neurodegenerative an...
2025-11-04 20:00
